OPRI’s Research & Development Programs are a novel initiative and the first of their kind in Singapore, bringing together experts in the field of respiratory disease to identify and address scientific uncertainties. Each program encompasses 4 key elements:
Registries are well established tools to prospectively monitor treatment benefits and risks over time, through the collection of natural history data, and aid the development of new therapeutics and/or diagnostics. They can be used to gather information on disease progression and patient subgroups, facilitate patient recruitment into clinical trials, and generate real world evidence on the safety and cost effectiveness of new therapeutics.
Databases contains routinely collected data, both clinical and non-clinical. Databases provide an essential source of real-world data to promote evidence-based research on the clinical and economic effectiveness of treatment in a real-life practice setting. OPRI has been leading the paradigm shift in real world evidence for the past 12 years, by utilising electronic medical records (EMR) and large claims databases to publish widely around the world.
Pragmatic trials invoke randomisation, typically in a broader range of patients and study sites. The outcomes of interest tend to include a greater emphasis on quality of life and long term clinical impact, than the typical randomised controlled trial (RCT) providing the true risks, benefits and costs of an intervention in routine clinical practice (real-life).
4. Implementation Research
Implementation research links research and practice by focusing on the implementation of programs, treatments and policies through application of knowledge in a real life clinical setting. OPRI utilises electronic medical record (EMR) tools and and quality improvement programs to improve the efficiency and effectiveness in primary care.